Tamoxifen is a prodrug given to inhibit tumor growth in patients with breast cancer. An active metabolite of tamoxifen, formed by CYP2D6, is responsible for its anti-tumor effects. If a patient is prescribed another drug that strongly inhibits CYP2D6, what effect do you predict for tamoxifen?
